DDInter843 DDInter1658
An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Griseofulvin {u} (Compound) binds {v} (Gene) KRT12
Griseofulvin {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Mitosis
Griseofulvin {u} (Compound) downregulates {v} (Gene) CCDC86
Griseofulvin {u} (Compound) causes {v} (Side Effect) Neuropathy peripheral
Griseofulvin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Griseofulvin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Griseofulvin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naloxegol
Griseofulvin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mirtazapine
Griseofulvin {u} may lead to a major life threatening interaction when taken with {v} Norgestimate
Griseofulvin {u} may lead to a major life threatening interaction when taken with {v} Etonogestrel
Griseofulvin (Compound) binds KRT12 (Gene)
Griseofulvin (Compound) is included by Decreased Mitosis (Pharmacologic Class)
Griseofulvin (Compound) downregulates CCDC86 (Gene)
Griseofulvin (Compound) causes Neuropathy peripheral (Side Effect)
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Dolutegravir
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine
Griseofulvin may lead to a major life threatening interaction when taken with Norgestimate
Griseofulvin may lead to a major life threatening interaction when taken with Etonogestrel